| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2013-11-01 | hRESCAP® (recombinant human Alkaline Phosphatase) | 1 | TNO (The Netherlands) Alloksys Life Sciences (The Netherlands) | ||
| 2013-10-29 | ADX71149 (JNJ-40411813) | adults with major depressive disorder who are also suffering anxiety symptoms | 2 | Janssen Research & Development (J&J - USA) Addex Therapeutics (Switzerland) | Mental diseases - CNS diseases |
| 2013-10-29 | undisclosed Nanobody® | Alzheimer's disease | 1 | Boehringer Ingelheim (Germany) | Neurodegenerative diseases |
| 2013-10-28 | ARISk® Test | autism |
Integragen (France) | Neurodevelopmental diseases | |
| 2013-10-28 | PF-05280014 [Trastuzumab-Pfizer] | metastatic breast cancer | 3 | Pfizer (USA - NY) | Cancer - Oncology |
| 2013-10-25 | RPL554 | chronic obstructive pulmonary disease (COPD) | Verona Pharma (UK) | Respiratory diseases | |
| 2013-10-22 | Debio 0932 and everolimus (Afinitor®) | advanced metastatic renal cell carcinoma |
1 | Curis (USA) Debiopharm (Switzerland) | Cancer - Oncology |
| 2013-10-21 | Eylea® (VEGF trap eye - aflibercept) | macular edema following branch retinal vein occlusion (BRVO) |
3 | Bayer Healthcare (Germany) Regeneron Pharmaceuticals (USA) | Ophtalmological diseases |
| 2013-10-21 | SAR566658 | CA6-positive cancers | 1 | ImmunoGen (USA) Sanofi (France) | Cancer - Oncology |
| 2013-10-19 | tepotinib | non-small cell lung cancer | 1-2 | Merck KGaA (Germany) | Cancer - Oncology |
| 2013-10-18 | MGN1404 - MIDGE® vector | melanoma | 1 | Mologen (Germany) | Cancer - Oncology |
| 2013-10-17 | UshStat® | Usher syndrome type 1B | 1-2a | Oxford BioMedica (UK) Sanofi (France) | Ophtalmological diseases |
| 2013-10-17 | StarGen® | Stargardt's disease |
1-2 | Oxford Biomedica (UK) Sanofi (France) | Rare diseases - Ophtalmological diseases - Genetic diseases |
| 2013-10-15 | APD515, an optimised oromucosal formulation of a currently marketed drug (a muscarinic agonist) | xerostemia (dry mouth) in advanced cancer patients | 2 | Acacia Pharma (UK) | Cancer - Oncology |
| 2013-10-14 | PRX-112 (oral glucocerebrosidase) | Gaucher disease | 1 | Protalix BioTherapeutics (Israel) | Rare diseases |
| 2013-10-14 | mangafodipir | patients with acute myocardial infarction undergoing percutaneous coronary intervention (PCI) | 2a | PledPharma (Sweden) | Cardiovascular diseases |
| 2013-10-10 | SG100 | allergic asthma caused by house dust mite (HDM) allergens | S-TARget therapeutics (Austria) | Allergic diseases - Inflammatory diseases - Respiratory diseases | |
| 2013-10-10 | ofatumumab | relapsing-remitting multiple sclerosis (RRMS) | 2 | Genmab (Denmark) GSK (UK) | Autoimmune diseases - Neurodegenerative diseases |
| 2013-10-10 | Lu AE58054 (idalopirdine) | Alzheimer’s disease | 3 | Lundbeck (Denmark) | Neurodegenerative diseases |
| 2013-10-10 | LL-37 | hard-to-heal venous leg ulcers | 1-2 | Pergamum (Sweden) | Cardiovascular diseases |
